In prostate cancer, E2F-related gene signatures encompassing CDKN2C can be used to stratify recurrence risk, with higher signature expression predicting worse recurrence-free survival, which is consistent with net pathway activation despite the nominal inhibitory role of CDKN2C [46]. This evidence concerns the gene CDKN2C and prostate cancer.